Seattle Genetics/ US81181C1045 /
12/13/2023 10:19:51 PM | Chg. - | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
228.86USD | - | 577,731 Turnover: 132.25 mill. |
-Bid Size: - | -Ask Size: - | 43.15 bill.USD | - | - |
GlobeNewswire
3/4
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of ...
GlobeNewswire
3/14/2022
Avadel Pharmaceuticals Announces Appointment of Brandi Robinson as Senior Vice President, Corporate ...
GlobeNewswire
1/18/2022
Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D.
GlobeNewswire
1/10/2022
Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts
GlobeNewswire
11/15/2021
Recludix Pharma Launches with $60 Million Series A to Support Innovative Platform to Discover and De...
GlobeNewswire
10/26/2021
Harpoon Therapeutics Announces Change to Management Team and Board of Directors
GlobeNewswire
10/14/2021
Nurix Therapeutics Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate Upda...
GlobeNewswire
8/25/2021
Caribou Biosciences Appoints Nancy Whiting, Pharm.D., to its Board of Directors
GlobeNewswire
7/13/2021
Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Upd...
GlobeNewswire
6/1/2021
Nurix Therapeutics Appoints Industry Leader Clay Siegall, Ph.D., to its Board of Directors
GlobeNewswire
9/21/2020
Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurr...
GlobeNewswire
9/10/2020
GW Pharmaceuticals Announces the Appointment of David Gryska to its Board of Directors